Archives
-
HSP90 Modulates RNA Foci in Myotonic Dystrophy Type 1
2026-09-11
Johnson and colleagues used an unbiased small-molecule RNA-FISH screen to identify HSP90 as a regulator of pathogenic DMPK RNA and CUG-repeat RNA foci in DM1 myoblasts. Their results connect HSP90 to p-STAT3 signaling and show that the response changes with muscle-cell differentiation, providing a mechanistic framework for studying RNA-foci homeostasis rather than a simple universal drug effect.
-
Protease Inhibitor Cocktail for MS Workflows
2026-09-10
Learn how to use a Protease Inhibitor Cocktail to preserve cell, tissue, and viral protein samples without introducing AEBSF-related mass-spectrometry concerns. This workflow also translates recent Lassa virus spike findings into practical choices for pH-controlled extraction, structural assays, and proteomics.
-
AEBSF.HCl: Serine Protease Inhibition Guide
2026-09-10
AEBSF.HCl, also called 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, is an irreversible broad-spectrum serine protease inhibitor for controlled cellular and biochemical experiments. Product and literature-linked benchmarks support its use in APP cleavage studies, amyloid-beta research, leukemic cell lysis assays, and carefully controlled protease experiments.
-
Adefovir (GS-0393): HBV Mechanism and Research Use
2026-09-09
Adefovir (GS-0393) is an acyclic nucleotide analog that becomes adefovir diphosphate and inhibits HBV DNA polymerase. This article consolidates its mechanism, quantitative assay benchmarks, OAT1 transporter use, workflow parameters, and research limitations.
-
Resveratrol Assay Workflows for Reliable Cell Data
2026-09-09
This scenario-driven guide explains how Resveratrol SKU A4182 can improve interpretation of cell viability, apoptosis, and mitochondrial assays. It connects SIRT1 biology with practical stock preparation, vehicle controls, pathway-resolved readouts, and evidence-based vendor selection.
-
AMPK, ULK1, and Autophagy Under Energy Stress
2026-09-08
The reference study challenges the prevailing view that AMPK uniformly activates autophagy during energy shortage. Its experiments show that AMPK suppresses ULK1-dependent autophagy initiation during severe energy stress while preserving the autophagy machinery for recovery, providing a more nuanced framework for interpreting autophagy signaling and kinase-inhibitor experiments.
-
DNA Damage Biomarkers Strengthen Micronucleus Assays
2026-09-08
Avlasevich and colleagues combined flow-cytometric micronucleus scoring with DNA damage response biomarkers to distinguish bona fide genotoxicity from cytotoxicity-associated irrelevant positives. The study shows that requiring concordant biomarker responses can substantially improve assay specificity while preserving sensitivity and can provide useful mode-of-action and potency information.
-
5-Azacytidine Reprograms Dormant Cancer Cells
2026-09-07
The 2023 Cell Reports study shows that 5-Azacytidine followed by retinoic acid can reprogram disseminated cancer cells into a stable, nonproliferative state rather than simply eliminate them. By restoring TGF-β–SMAD4 signaling, the combination suppressed metastatic outgrowth in experimental head and neck cancer models and identified SMAD4 as a key determinant of response.
-
Nilotinib (AMN-107): A Mechanism-First Research Guide
2026-09-07
Nilotinib and AMN-107 are powerful tools for dissecting BCR-ABL signaling, mutant kinase biology, and assay-dependent phosphorylation outcomes. This guide connects target engagement with phosphatase-regulated signaling to improve experimental design in leukemia and kinase-driven tumor research.
-
Imipramine Workflows for Autophagy and Apoptosis
2026-09-05
Imipramine provides a practical perturbation tool for connecting glioma autophagy, leukemia apoptosis, neuroprotection, and immune signaling in controlled cell-based experiments. This guide translates ceramide–autophagy findings from fish nodavirus research into careful assay design without overstating Imipramine as an antiviral treatment.
-
TRIM21–ERK1/2 Drives Pituitary Adenoma Resistance
2026-09-04
The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, proliferation, and dopamine-agonist resistance in pituitary adenomas. Its combination of CRISPR screening, biochemical validation, animal studies, and NanoBiT drug screening nominates TRIM21 suppression as a research strategy, while requiring further disease-specific validation of Quisinostat and related compounds.
-
Carbapenemase Gene Transmission in Enterobacter cloacae
2026-09-04
A 2025 BMC Microbiology study characterized carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, China. Its combination of gene-localization, antimicrobial susceptibility, conjugation, mobile-element, and genotyping analyses shows that blaNDM-1-associated resistance was widespread and had substantial potential for both horizontal and clonal dissemination.
-
Sisomicin Workflows for Translational Antibacterial Research
2026-09-03
Sisomicin supports quantitative antibacterial testing across Gram-negative screens, Gram-positive models, and carefully designed intra- and extracellular assays. This workflow translates a dual-compartment infection model into practical decisions about controls, concentration ranges, pharmacodynamic readouts, and troubleshooting.
-
Protecting Phospho-Signaling in HCC Protein Workflows
2026-09-03
A translational framework for using EDTA-free protease inhibition to preserve Sp1 succinylation and mTOR phosphorylation measurements in hepatocellular carcinoma research.
-
RepSox: Selective ALK5 Inhibitor for iPSC Research
2026-09-02
RepSox is a potent and selective ALK5 inhibitor with a reported IC50 of 4 nM in the manufacturer’s product information. It is used to investigate TGF-β signaling pathway inhibition, Sox2-independent induced pluripotent stem cell reprogramming, and related cell differentiation research, but direct evidence for RepSox in the cited platelet-differentiation protocol is not established.